首頁 > 市場調查報告書 > 醫療設備

婦科治療

市場調查報告書

商品編碼

1506305

子宮肌瘤:市場洞察·流行病學·市場預測 (～2034年)

Uterine fibroids - Market Insight, Epidemiology, and Market Forecast - 2034

出版日期: 2024年06月01日 | 出版商:

DelveInsight | 英文 200 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

本報告提供全球主要7個國家子宮肌瘤的市場調查，彙整疾病的背景·概要，流行病學，治療和管理概要，推動市場要素與阻礙，未滿足需求，上市藥及開發平台藥物的簡介，主要國家的市場規模的轉變·預測，競爭情形等資料，以及最好的機會，評價市場潛在力等資訊。

對象地區

美國
歐洲5個國家(德國·法國·義大利·西班牙·英國)
日本

調查期間:2020年～2034年

報告要點

由於意識的變化，子宮肌瘤市場將持續增長由於醫療保健需求的增加和全球醫療保健支出的增加，預計這種情況在未來幾年將發生變化。
公司和研究機構正在努力分析可能影響子宮肌瘤研究和開發的課題並探索機會。正在開發的療法著重於治療/改善疾病狀況的新方法。
各大公司正致力於開發治療子宮肌瘤的藥物。新治療藥物的推出預計將對市場產生重大影響。
開發子宮肌瘤的新治療藥物需要更深入地了解疾病的病理學。
依開發階段（第三階段和第二階段）對我們的管道資產進行深入分析，包括各種新興趨勢、詳細的臨床概況、關鍵交叉競爭、上市日期和產品線藥物開發活動比較分析，為客戶提供協助。

DelveInsight's "Uterine fibroids - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Uterine fibroids, historical and forecasted epidemiology as well as the Uterine fibroids market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Uterine fibroids market report provides current treatment practices, emerging drugs, Uterine fibroids market share of the individual therapies, current and forecasted Uterine fibroids market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Uterine fibroids treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2020-2034

Uterine fibroids Disease Understanding and Treatment Algorithm

The DelveInsight Uterine fibroids market report gives a thorough understanding of the Uterine fibroids by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Uterine fibroids.

Treatment

It covers the details of conventional and current medical therapies available in the Uterine fibroids market for the treatment of the condition. It also provides Uterine fibroids treatment algorithms and guidelines in the United States, Europe, and Japan.

Uterine fibroids Epidemiology

The Uterine fibroids epidemiology division provide insights about historical and current Uterine fibroids patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Uterine fibroids epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Uterine fibroids Epidemiology

The epidemiology segment also provides the Uterine fibroids epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Uterine fibroids Drug Chapters

Drug chapter segment of the Uterine fibroids report encloses the detailed analysis of Uterine fibroids marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Uterine fibroids clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Uterine fibroids treatment.

Uterine fibroids Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Uterine fibroids treatment.

Uterine fibroids Market Outlook

The Uterine fibroids market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Uterine fibroids market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Uterine fibroids market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Uterine fibroids market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Uterine fibroids market in 7MM.

The United States Market Outlook

This section provides the total Uterine fibroids market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Uterine fibroids market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Uterine fibroids market size and market size by therapies in Japan is also mentioned.

Uterine fibroids Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Uterine fibroids market or expected to get launched in the market during the study period 2020-2034. The analysis covers Uterine fibroids market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Uterine fibroids Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Uterine fibroids key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Uterine fibroids emerging therapies.

Reimbursement Scenario in Uterine fibroids

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Uterine fibroids domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Uterine fibroids market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Uterine fibroids Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

The report covers the descriptive overview of Uterine fibroids, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
Comprehensive insight has been provided into the Uterine fibroids epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Uterine fibroids are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Uterine fibroids market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Uterine fibroids market

Report Highlights:

In the coming years, Uterine fibroids market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Uterine fibroids R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Uterine fibroids. Launch of emerging therapies will significantly impact the Uterine fibroids market
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Uterine fibroids
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Uterine fibroids Report Insights

Patient Population
Therapeutic Approaches
Uterine fibroids Pipeline Analysis
Uterine fibroids Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Uterine fibroids Report Key Strengths

11 Years Forecast
7MM Coverage
Uterine fibroids Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Uterine fibroids Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Questions:

Market Insights:

What was the Uterine fibroids market share (%) distribution in 2020 and how it would look like in 2034?
What would be the Uterine fibroids total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
What are the key findings pertaining to the market across 7MM and which country will have the largest Uterine fibroids market size during the forecast period (2024-2034)?
At what CAGR, the Uterine fibroids market is expected to grow in 7MM during the forecast period (2020-2034)?
What would be the Uterine fibroids market outlook across the 7MM during the forecast period (2020-2034)?
What would be the Uterine fibroids market growth till 2032, and what will be the resultant market Size in the year 2034?
How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

What is the disease risk, burden and unmet needs of the Uterine fibroids?
What is the historical Uterine fibroids patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of Uterine fibroids in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Uterine fibroids?
Out of all 7MM countries, which country would have the highest prevalent population of Uterine fibroids during the forecast period (2020-2034)?
At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

What are the current options for the Uterine fibroids treatment, along with the approved therapy?
What are the current treatment guidelines for the treatment of Uterine fibroids in the USA, Europe, and Japan?
What are the Uterine fibroids marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
How many companies are developing therapies for the treatment of Uterine fibroids?
How many therapies are developed by each company for Uterine fibroids treatment?
How many are emerging therapies in mid-stage, and late stage of development for Uterine fibroids treatment?
What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Uterine fibroids therapies?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Uterine fibroids and their status?
What are the key designations that have been granted for the emerging therapies for Uterine fibroids?
What are the global historical and forecasted market of Uterine fibroids?

Reasons to buy:

The report will help in developing business strategies by understanding trends shaping and driving the Uterine fibroids market
To understand the future market competition in the Uterine fibroids market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for Uterine fibroids in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for Uterine fibroids market
To understand the future market competition in the Uterine fibroids market

1. Key Insights

2. Executive Summary of Uterine fibroids

3. Competitive Intelligence Analysis for Uterine fibroids

4. Uterine fibroids: Market Overview at a Glance

4.1. Uterine fibroids Total Market Share (%) Distribution in 2020
4.2. Uterine fibroids Total Market Share (%) Distribution in 2034

5. Uterine fibroids: Disease Background and Overview

5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis

6. Patient Journey

7. Uterine fibroids Epidemiology and Patient Population

7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
- 7.3.1. Uterine fibroids Epidemiology Scenario in the 7MM (2020-2034)
7.4. United States Epidemiology
- 7.4.1. Uterine fibroids Epidemiology Scenario in the United States (2020-2034)
7.5. EU-5 Country-wise Epidemiology
- 7.5.1. Germany Epidemiology
  - 7.5.1.1. Uterine fibroids Epidemiology Scenario in Germany (2020-2034)
- 7.5.2. France Epidemiology
  - 7.5.2.1. Uterine fibroids Epidemiology Scenario in France (2020-2034)
- 7.5.3. Italy Epidemiology
  - 7.5.3.1. Uterine fibroids Epidemiology Scenario in Italy (2020-2034)
- 7.5.4. Spain Epidemiology
  - 7.5.4.1. Uterine fibroids Epidemiology Scenario in Spain (2020-2034)
- 7.5.5. United Kingdom Epidemiology
  - 7.5.5.1. Uterine fibroids Epidemiology Scenario in the United Kingdom (2020-2034)
- 7.5.6. Japan Epidemiology
  - 7.5.6.1. Uterine fibroids Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Uterine fibroids Treatment and Management
8.2. Uterine fibroids Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Uterine fibroids Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
- 11.2.1. Product Description
- 11.2.2. Regulatory Milestones
- 11.2.3. Other Developmental Activities
- 11.2.4. Pivotal Clinical Trials
- 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross
12.2. Drug Name: Company Name
- 12.2.1. Product Description
- 12.2.2. Other Developmental Activities
- 12.2.3. Clinical Development
- 12.2.4. Safety and Efficacy
- 12.2.5. Product Profile

List to be continued in report

13. Uterine fibroids: Seven Major Market Analysis

13.1. Key Findings
13.2. Uterine fibroids Market Size in 7MM
13.3. Uterine fibroids Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size
- 15.1.1. Uterine fibroids Total Market Size in the United States
- 15.1.2. Uterine fibroids Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
- 15.3.1. Uterine fibroids Total Market Size in Germany
- 15.3.2. Uterine fibroids Market Size by Therapies in Germany
15.4. France Market Size
- 15.4.1. Uterine fibroids Total Market Size in France
- 15.4.2. Uterine fibroids Market Size by Therapies in France
15.5. Italy Market Size
- 15.5.1. Uterine fibroids Total Market Size in Italy
- 15.5.2. Uterine fibroids Market Size by Therapies in Italy
15.6. Spain Market Size
- 15.6.1. Uterine fibroids Total Market Size in Spain
- 15.6.2. Uterine fibroids Market Size by Therapies in Spain
15.7. United Kingdom Market Size
- 15.7.1. Uterine fibroids Total Market Size in the United Kingdom
- 15.7.2. Uterine fibroids Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
- 15.8.1. Japan Market Size
- 15.8.2. Uterine fibroids Total Market Size in Japan
- 15.8.3. Uterine fibroids Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Uterine fibroids

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography
20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.

簡介目錄圖表

List of Tables

Table 1: 7MM Uterine fibroids Epidemiology (2020-2034)
Table 2: 7MM Uterine fibroids Diagnosed and Treatable Cases (2020-2034)
Table 3: Uterine fibroids Epidemiology in the United States (2020-2034)
Table 4: Uterine fibroids Diagnosed and Treatable Cases in the United States (2020-2034)
Table 5: Uterine fibroids Epidemiology in Germany (2020-2034)
Table 6: Uterine fibroids Diagnosed and Treatable Cases in Germany (2020-2034)
Table 7: Uterine fibroids Epidemiology in France (2020-2034)
Table 8: Uterine fibroids Diagnosed and Treatable Cases in France (2020-2034)
Table 9: Uterine fibroids Epidemiology in Italy (2020-2034)
Table 10: Uterine fibroids Diagnosed and Treatable Cases in Italy (2020-2034)
Table 11: Uterine fibroids Epidemiology in Spain (2020-2034)
Table 12: Uterine fibroids Diagnosed and Treatable Cases in Spain (2020-2034)
Table 13: Uterine fibroids Epidemiology in the UK (2020-2034)
Table 14: Uterine fibroids Diagnosed and Treatable Cases in the UK (2020-2034)
Table 15: Uterine fibroids Epidemiology in Japan (2020-2034)
Table 16: Uterine fibroids Diagnosed and Treatable Cases in Japan (2020-2034)
Table 17: Drug Name, Clinical Trials by Recruitment status
Table 18: Drug Name, Clinical Trials by Zone
Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
Table 20: Region-wise Market Size in USD, Million (2020-2034)
Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
Table 22: United States Market Size in USD, Million (2020-2034)
Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
Table 24: Germany Market Size in USD, Million (2020-2034)
Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
Table 26: France Market Size in USD, Million (2020-2034)
Table 27: France Market Size by Therapy in USD, Million (2020-2034)
Table 28: Italy Market Size in USD, Million (2020-2034)
Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
Table 30: Spain Market Size in USD, Million (2020-2034)
Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
Table 32: United Kingdom Market Size in USD, Million (2020-2034)
Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
Table 34: Japan Market Size in USD, Million (2020-2034)
Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

Figure 1: 7MM Uterine fibroids Epidemiology (2020-2034)
Figure 2: 7MM Uterine fibroids Diagnosed and Treatable Cases (2020-2034)
Figure 3: Uterine fibroids Epidemiology in the United States (2020-2034)
Figure 4: Uterine fibroids Diagnosed and Treatable Cases in the United States (2020-2034)
Figure 5: Uterine fibroids Epidemiology in Germany (2020-2034)
Figure 6: Uterine fibroids Diagnosed and Treatable Cases in Germany (2020-2034)
Figure 7: Uterine fibroids Epidemiology in France (2020-2034)
Figure 8: Uterine fibroids Diagnosed and Treatable Cases in France (2020-2034)
Figure 9: Uterine fibroids Epidemiology in Italy (2020-2034)
Figure 10: Uterine fibroids Diagnosed and Treatable Cases in Italy (2020-2034)
Figure 11: Uterine fibroids Epidemiology in Spain (2020-2034)
Figure 12: Uterine fibroids Diagnosed and Treatable Cases in Spain (2020-2034)
Figure 13: Uterine fibroids Epidemiology in the UK (2020-2034)
Figure 14: Uterine fibroids Diagnosed and Treatable Cases in the UK (2020-2034)
Figure 15: Uterine fibroids Epidemiology in Japan (2020-2034)
Figure 16: Uterine fibroids Diagnosed and Treatable Cases in Japan (2020-2034)
Figure 17: Drug Name, Clinical Trials by Recruitment status
Figure 18: Drug Name, Clinical Trials by Zone
Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
Figure 20: Region-wise Market Size in USD, Million (2020-2034)
Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
Figure 22: United States Market Size in USD, Million (2020-2034)
Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
Figure 24: Germany Market Size in USD, Million (2020-2034)
Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
Figure 26: France Market Size in USD, Million (2020-2034)
Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
Figure 28: Italy Market Size in USD, Million (2020-2034)
Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
Figure 30: Spain Market Size in USD, Million (2020-2034)
Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
Figure 34: Japan Market Size in USD, Million (2020-2034)
Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)